Entities / Company
PureTech Ventures.
american company
- Reports this week
- 0
- Active events
- 0
- Connections
- 21
What's happening
Gone quiet
No new reports in 90+ days-
PureTech Ventures launched Celea, a new respiratory disease treatment, with Sven Dethlefs appointed to lead its program advancement.Some support2 reports1 development inside
-
PureTech Ventures received FDA approval for its medicines on July 9, 2025. Raju Kucherlapati and Robert Langer were involved in the company's board.Some support1 report
-
Leadership appointments at PureTech Ventures include the appointment of Robert Lyne as Interim CEO and Sharon Barber-Lui as Interim Chair of the Board.Some support1 report
-
DiaMedica Therapeutics appointed Julie Krop as Chief Medical Officer, succeeding Lorianne Masuoka.Some support1 report
-
PureTech Ventures filed Form 6-K with the US SEC on August 28, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around PureTech Ventures this week
News at the entities that move PureTech Ventures most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves PureTech Ventures
Connections
The 1 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
PureTech Ventures' market viability and product access are structurally dependent on regulatory approval from the FDA.
History
Events by the month they beganJune 2026
5 events- PureTech Ventures launched Celea, a new respiratory disease treatment, with Sven Dethlefs appointed to lead its program advancement.
- PureTech Ventures received FDA approval for its medicines on July 9, 2025. Raju Kucherlapati and Robert Langer were involved in the company's board.
- Leadership appointments at PureTech Ventures include the appointment of Robert Lyne as Interim CEO and Sharon Barber-Lui as Interim Chair of the Board.
- DiaMedica Therapeutics appointed Julie Krop as Chief Medical Officer, succeeding Lorianne Masuoka.
- PureTech Ventures filed Form 6-K with the US SEC on August 28, 2025.